priors.science/reviews/rheumatoid-arthritis-targeted-therapy

Rheumatoid Arthritis Targeted Therapy

The current evidence on 6 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

6claims tracked

104primary papers reviewed

4 Oct 2026latest evidence review

0 Established · 4 Likely · 1 Uncertain · 1 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

TNF inhibitors improve response and slow radiographic progression in methotrexate-inadequate rheumatoid arthritisTNF BiologicsLikely81%19

Interleukin-6 receptor inhibitors achieve responses in rheumatoid arthritis, tocilizumab superior to adalimumabNon TNF BiologicsLikely73%15

JAK inhibitors match biologic disease-modifying antirheumatic drugs for remission in rheumatoid arthritis, given orallyJAK InhibitorsLikely73%25

Abatacept and rituximab match TNF inhibitors in rheumatoid arthritisNon TNF BiologicsLikely73%25

Treat-to-target strategy improves outcomes versus routine care in rheumatoid arthritisT2T StrategyUncertain58%13

Tofacitinib cardiovascular and malignancy safety signal reflects a JAK class effectJAK InhibitorsDoubtful32%10

Track Rheumatoid Arthritis Targeted Therapy.

These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing: what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it. Confidently false as stated.

A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.